RB Capital Management LLC Sells 71 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

RB Capital Management LLC lessened its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,626 shares of the medical equipment provider’s stock after selling 71 shares during the period. RB Capital Management LLC’s holdings in Intuitive Surgical were worth $549,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ISRG. WCM Investment Management LLC purchased a new stake in Intuitive Surgical during the 4th quarter valued at about $575,536,000. International Assets Investment Management LLC increased its holdings in Intuitive Surgical by 32,360.5% during the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after purchasing an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd lifted its holdings in Intuitive Surgical by 113.2% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after buying an additional 677,455 shares during the period. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Intuitive Surgical in the third quarter valued at $178,667,000. Finally, Quadrature Capital Ltd boosted its position in Intuitive Surgical by 466.2% during the 3rd quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock valued at $99,601,000 after acquiring an additional 280,480 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction on Monday, April 29th. The shares were sold at an average price of $375.39, for a total value of $141,146.64. Following the completion of the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at $2,067,272.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $375.39, for a total transaction of $141,146.64. Following the completion of the sale, the executive vice president now owns 5,507 shares in the company, valued at approximately $2,067,272.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now owns 25,319 shares in the company, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 226,967 shares of company stock valued at $87,848,586. 0.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ISRG. BTIG Research increased their price objective on Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Truist Financial boosted their price target on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Mizuho raised their price objective on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Finally, Barclays raised their target price on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Trading Up 0.3 %

Shares of Intuitive Surgical stock traded up $1.08 on Wednesday, hitting $371.70. 941,461 shares of the company traded hands, compared to its average volume of 1,636,208. The stock’s 50 day moving average price is $385.96 and its 200-day moving average price is $348.19. The company has a market cap of $131.84 billion, a PE ratio of 66.90, a PEG ratio of 4.83 and a beta of 1.36. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. Intuitive Surgical’s revenue was up 11.5% on a year-over-year basis. During the same period last year, the firm posted $1.00 EPS. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.